Who are Placebo and SSRI's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zoloft, Paroxetine + relaxation.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-and-ssri.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Placebo and SSRI — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo and SSRI (Placebo and SSRI) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SSRI (Selective Serotonin Reuptake Inhibitor). Area: Psychiatry / Mental Health.

marketed SSRI (Selective Serotonin Reuptake Inhibitor) Serotonin transporter (SERT) Psychiatry / Mental Health Small molecule Live · refreshed every 30 min

Target snapshot

Placebo and SSRI (Placebo and SSRI) — All India Institute of Medical Sciences, Bhubaneswar. SSRIs increase synaptic serotonin by inhibiting its reuptake, while placebo provides a control comparator with no active pharmacological mechanism.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo and SSRI TARGET	Placebo and SSRI	All India Institute of Medical Sciences, Bhubaneswar	marketed	SSRI (Selective Serotonin Reuptake Inhibitor)	Serotonin transporter (SERT)
Zoloft	sertraline	Pfizer Inc.	marketed	SSRI (Selective serotonin reuptake inhibitor)	Cytochrome P450 2C19, Melanocortin receptor 5, 5-hydroxytryptamine receptor 2A	1991-12-30
Paroxetine + relaxation	Paroxetine + relaxation	University of Göttingen	marketed	SSRI (Selective Serotonin Reuptake Inhibitor)	Serotonin transporter (SERT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SSRI (Selective Serotonin Reuptake Inhibitor) class)

All India Institute of Medical Sciences, Bhubaneswar · 1 drug in this class
University of Göttingen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo and SSRI — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-and-ssri. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab